When the government responded that it was introducing a double price system instead of opposing the National Assembly's criticism that incentives such as exclusion and suspension of PVA should be given to new domestic drugs, the domestic pharmaceutical industry negatively evaluated it as an "empty talk-style administration." Critics say that PVA has virtually no complementarity and that there are no cases of new domestic drugs that benefit from the double price system.

On the 2nd, the domestic pharmaceutical industry is disappointed with the MOHW's position on the issue of "Exclusion and Suspension of New Drugs for Development of Innovative Pharmaceutical Companies," which has become a hot topic during